Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18145188 | 1.00 | POLA1 (0.33) | POLA1PPM1BPTPN1PPP1CCSMN1; SMN2 | |
| SCHEMBL6175009 | 0.90 | PPM1B (0.36) | POLA1PPM1BPTPN1PPP1CC | |
| SCHEMBL11108301 | 0.90 | PPM1B (0.36) | PPM1BPTPN1PPP1CC | |
| SCHEMBL11149803 | 0.83 | POLA1 (0.33) | POLA1 | |
| SCHEMBL10965463 | 0.81 | HTT (0.33) | PPM1BPTPN1PPP1CC | |
| SCHEMBL1791944 | 0.79 | POLB (0.33) | — | |
| SCHEMBL11103866 | 0.77 | TSHR (0.33) | — | |
| SCHEMBL30385379 | 0.75 | PPM1B (0.37) | PPM1BPTPN1PPP1CC | |
| SCHEMBL23441667 | 0.74 | TP53 (0.40) | — | |
| SCHEMBL14074016 | 0.74 | POLB (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379485-A4 | SELECTIVE RING-OPENING CROSS-METATHESIS OF CYCLOOLEFINS | CALIFORNIA INST OF TECHN (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6803429-B2 | CONTACTING THE CYCLIC OLEFIN WITH THE SECOND OLEFINIC REACTANT IN THE PRESENCE OF A CATALYST COMPOSED OF A GROUP 8 TRANSITION METAL ALKYLIDENE COMPLEX UNDER CONDITIONS AND FOR A TIME PERIOD EFFECTIVE TO ALLOW THE ROCM REACTION TO OCCUR | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-10-12 | — | — | US | disclosed |
| EP-1379485-A1 | SELECTIVE RING-OPENING CROSS-METATHESIS OF CYCLOOLEFINS | California Institute of Technology (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20020198426-A1 | Selective ring-opening cross-metathesis of cycloolefins | CYMETECH, LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002079127-A1 | SELECTIVE RING-OPENING CROSS-METATHESIS OF CYCLOOLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198426-A1 | Selective ring-opening cross-metathesis of cycloolefins | KMO, COASY, OXER1 | POLA1 1946/4885PPM1B 4871/4885PTPN1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.